Online inquiry

IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10578MR)

This product GTTS-WQ10578MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ANGPT2 gene. The antibody can be applied in Solid tumors, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001118887.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 285
UniProt ID O15123
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10578MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9686MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64304500
GTTS-WQ12087MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MOR-03087
GTTS-WQ8113MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ3132MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA APT070
GTTS-WQ859MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-176
GTTS-WQ11599MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MGAH-22
GTTS-WQ8900MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IGE25
GTTS-WQ14046MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA aLAG367
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW